https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2022.1046584/full
Frontiers | Lenvatinib plus anti-PD-1 therapy represents a feasible conversion resection strategy...
Purpose: We aimed to investigate the feasibility of lenvatinib plus anti-PD-1 therapy as a downstaging conversion therapy for initially unresectable hepatoce...
anti pd 1
https://www.fiercebiotech.com/biotech/agenus-fda-approval-site-showcases-anti-pd-1-drug-data
Agenus, with FDA approval in sight, showcases anti-PD-1 data | Fierce Biotech
Aug 27, 2021 - Agenus is now in the closing stretch of its multidecade effort to bring a drug to market.
anti pd 1